| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epoprostenol | 23 | 2021 | 69 | 5.510 |
Why?
|
| Dinoprostone | 12 | 2023 | 77 | 4.920 |
Why?
|
| Intramolecular Oxidoreductases | 21 | 2021 | 60 | 4.330 |
Why?
|
| Cytochrome P-450 Enzyme System | 20 | 2021 | 135 | 3.730 |
Why?
|
| Cyclooxygenase 1 | 12 | 2021 | 42 | 3.370 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 10 | 2010 | 11 | 2.340 |
Why?
|
| Arachidonic Acid | 12 | 2016 | 81 | 2.330 |
Why?
|
| Cyclooxygenase 2 | 10 | 2023 | 155 | 2.310 |
Why?
|
| Protein Engineering | 8 | 2021 | 73 | 1.910 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2023 | 307 | 1.880 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2023 | 293 | 1.590 |
Why?
|
| Prostaglandin H2 | 8 | 2019 | 12 | 1.460 |
Why?
|
| Thromboxane A2 | 6 | 2023 | 19 | 1.380 |
Why?
|
| Prostaglandin-E Synthases | 6 | 2023 | 11 | 1.350 |
Why?
|
| Thromboxane-A Synthase | 7 | 2019 | 16 | 1.310 |
Why?
|
| Receptors, Prostaglandin | 6 | 2018 | 22 | 1.260 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2022 | 57 | 1.260 |
Why?
|
| Models, Molecular | 18 | 2008 | 1079 | 1.220 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2019 | 771 | 1.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 11 | 2017 | 294 | 1.080 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 7 | 2021 | 83 | 1.060 |
Why?
|
| Antioxidants | 2 | 2021 | 369 | 1.040 |
Why?
|
| Receptors, Epoprostenol | 8 | 2007 | 15 | 0.980 |
Why?
|
| Thromboxanes | 2 | 2023 | 10 | 0.940 |
Why?
|
| Alprostadil | 2 | 2017 | 27 | 0.890 |
Why?
|
| Drug Discovery | 3 | 2018 | 171 | 0.890 |
Why?
|
| Megakaryocytes | 1 | 2023 | 42 | 0.850 |
Why?
|
| Neurodegenerative Diseases | 2 | 2016 | 250 | 0.850 |
Why?
|
| Up-Regulation | 2 | 2020 | 868 | 0.840 |
Why?
|
| Thrombosis | 2 | 2021 | 525 | 0.800 |
Why?
|
| Ligands | 11 | 2018 | 539 | 0.780 |
Why?
|
| Cannabidiol | 1 | 2021 | 22 | 0.750 |
Why?
|
| Recombinant Proteins | 12 | 2021 | 1398 | 0.740 |
Why?
|
| Benzene Derivatives | 1 | 2021 | 19 | 0.740 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 101 | 0.710 |
Why?
|
| Protein Conformation | 13 | 2010 | 834 | 0.710 |
Why?
|
| Protein Binding | 14 | 2018 | 1757 | 0.700 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 8 | 2008 | 43 | 0.690 |
Why?
|
| HEK293 Cells | 6 | 2021 | 735 | 0.690 |
Why?
|
| Receptors, Prostaglandin E | 2 | 2011 | 10 | 0.670 |
Why?
|
| Binding Sites | 15 | 2017 | 1304 | 0.660 |
Why?
|
| Amino Acid Sequence | 19 | 2008 | 2715 | 0.660 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 205 | 0.640 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 2 | 2017 | 4 | 0.620 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2011 | 19 | 0.610 |
Why?
|
| Molecular Sequence Data | 19 | 2008 | 3891 | 0.600 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 163 | 0.590 |
Why?
|
| Molecular Mimicry | 2 | 2008 | 26 | 0.590 |
Why?
|
| Disease Resistance | 1 | 2018 | 23 | 0.580 |
Why?
|
| Intracellular Membranes | 5 | 2006 | 63 | 0.570 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 3 | 2006 | 17 | 0.570 |
Why?
|
| Stroke | 2 | 2018 | 989 | 0.570 |
Why?
|
| Animals | 35 | 2021 | 34224 | 0.560 |
Why?
|
| Prostaglandins | 4 | 2018 | 48 | 0.550 |
Why?
|
| Endoplasmic Reticulum | 6 | 2016 | 217 | 0.550 |
Why?
|
| COS Cells | 9 | 2010 | 275 | 0.550 |
Why?
|
| Amino Acids | 1 | 2019 | 668 | 0.540 |
Why?
|
| Models, Chemical | 2 | 2007 | 86 | 0.530 |
Why?
|
| Protein Structure, Tertiary | 8 | 2005 | 767 | 0.530 |
Why?
|
| Microsomes | 5 | 2022 | 56 | 0.530 |
Why?
|
| Oxyquinoline | 1 | 2016 | 4 | 0.520 |
Why?
|
| Genetic Therapy | 5 | 2013 | 687 | 0.520 |
Why?
|
| Cell Line | 10 | 2020 | 2758 | 0.500 |
Why?
|
| Mutagenesis, Site-Directed | 7 | 2017 | 319 | 0.500 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 110 | 0.500 |
Why?
|
| Endoplasmic Reticulum, Smooth | 1 | 2015 | 2 | 0.490 |
Why?
|
| Protein Structure, Secondary | 8 | 2015 | 237 | 0.480 |
Why?
|
| Oxidative Stress | 2 | 2021 | 838 | 0.480 |
Why?
|
| Peptide Fragments | 6 | 2015 | 780 | 0.480 |
Why?
|
| Humans | 52 | 2023 | 125156 | 0.450 |
Why?
|
| Insulin | 1 | 2019 | 1204 | 0.450 |
Why?
|
| Hippocampus | 1 | 2020 | 824 | 0.440 |
Why?
|
| Receptors, Thromboxane | 2 | 2003 | 5 | 0.420 |
Why?
|
| Cells, Cultured | 5 | 2011 | 3054 | 0.410 |
Why?
|
| Iloprost | 3 | 2020 | 11 | 0.400 |
Why?
|
| Stem Cell Transplantation | 2 | 2013 | 238 | 0.380 |
Why?
|
| Crystallography, X-Ray | 4 | 2017 | 357 | 0.370 |
Why?
|
| Signal Transduction | 5 | 2017 | 4534 | 0.360 |
Why?
|
| Peptides | 7 | 2015 | 811 | 0.360 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 874 | 0.360 |
Why?
|
| Hypertension, Pulmonary | 3 | 2013 | 439 | 0.360 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 1043 | 0.350 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2010 | 19 | 0.350 |
Why?
|
| Adipocytes | 1 | 2011 | 141 | 0.340 |
Why?
|
| Heart Diseases | 2 | 2013 | 493 | 0.340 |
Why?
|
| Platelet Aggregation | 5 | 2019 | 121 | 0.340 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 2396 | 0.340 |
Why?
|
| Models, Biological | 1 | 2015 | 1460 | 0.330 |
Why?
|
| Neurons | 1 | 2020 | 1932 | 0.330 |
Why?
|
| Catalysis | 3 | 2021 | 127 | 0.320 |
Why?
|
| Mutagenesis | 2 | 2007 | 346 | 0.320 |
Why?
|
| Antihypertensive Agents | 2 | 2010 | 414 | 0.310 |
Why?
|
| Solutions | 5 | 2008 | 65 | 0.310 |
Why?
|
| Embryonic Stem Cells | 1 | 2010 | 163 | 0.310 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2009 | 292 | 0.310 |
Why?
|
| Down-Regulation | 1 | 2011 | 698 | 0.300 |
Why?
|
| Heart Arrest | 1 | 2013 | 354 | 0.300 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4393 | 0.300 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 206 | 0.300 |
Why?
|
| DNA, Complementary | 4 | 2017 | 462 | 0.290 |
Why?
|
| Regeneration | 1 | 2010 | 212 | 0.290 |
Why?
|
| Neoplasms | 2 | 2021 | 2794 | 0.270 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 4 | 2010 | 38 | 0.270 |
Why?
|
| Kinetics | 6 | 2009 | 1332 | 0.270 |
Why?
|
| Endometrium | 2 | 2006 | 281 | 0.260 |
Why?
|
| Prunella | 1 | 2006 | 2 | 0.260 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 443 | 0.260 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 2005 | 6 | 0.250 |
Why?
|
| Biomimetic Materials | 1 | 2005 | 11 | 0.250 |
Why?
|
| Calcium Signaling | 3 | 2017 | 244 | 0.240 |
Why?
|
| Substrate Specificity | 4 | 2007 | 295 | 0.240 |
Why?
|
| Heart | 1 | 2010 | 729 | 0.240 |
Why?
|
| Blood Pressure | 2 | 2013 | 1372 | 0.240 |
Why?
|
| Catalytic Domain | 3 | 2016 | 158 | 0.230 |
Why?
|
| MicroRNAs | 1 | 2011 | 836 | 0.220 |
Why?
|
| Mice | 10 | 2020 | 17635 | 0.220 |
Why?
|
| Delayed-Action Preparations | 1 | 2023 | 110 | 0.210 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2010 | 88 | 0.210 |
Why?
|
| Transfection | 5 | 2013 | 1068 | 0.210 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 179 | 0.210 |
Why?
|
| Receptors, Cholinergic | 3 | 1992 | 84 | 0.200 |
Why?
|
| Blood Platelets | 2 | 2023 | 327 | 0.190 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2021 | 50 | 0.190 |
Why?
|
| Circular Dichroism | 3 | 2009 | 86 | 0.190 |
Why?
|
| Maze Learning | 2 | 2020 | 128 | 0.190 |
Why?
|
| Epithelial Cells | 1 | 2006 | 909 | 0.180 |
Why?
|
| Cannabis | 1 | 2021 | 40 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 154 | 0.180 |
Why?
|
| Penis | 2 | 2013 | 97 | 0.170 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2013 | 241 | 0.170 |
Why?
|
| Celecoxib | 1 | 2019 | 32 | 0.170 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 309 | 0.170 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 331 | 0.160 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 345 | 0.160 |
Why?
|
| Hemostatics | 1 | 2019 | 57 | 0.160 |
Why?
|
| Models, Animal | 1 | 2021 | 463 | 0.160 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2005 | 658 | 0.160 |
Why?
|
| Sequence Alignment | 3 | 2005 | 621 | 0.150 |
Why?
|
| Spodoptera | 2 | 2008 | 44 | 0.150 |
Why?
|
| Baculoviridae | 2 | 2008 | 64 | 0.150 |
Why?
|
| Brain Diseases | 1 | 2021 | 300 | 0.150 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2012 | 166 | 0.150 |
Why?
|
| Erectile Dysfunction | 2 | 2013 | 181 | 0.150 |
Why?
|
| NFATC Transcription Factors | 1 | 2018 | 44 | 0.150 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 39 | 0.150 |
Why?
|
| Tryptophan | 2 | 2009 | 91 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 80 | 0.150 |
Why?
|
| Drug Design | 3 | 2008 | 152 | 0.140 |
Why?
|
| Cell Survival | 1 | 2020 | 813 | 0.140 |
Why?
|
| Colon | 1 | 2019 | 350 | 0.140 |
Why?
|
| Peptides, Cyclic | 2 | 2003 | 55 | 0.140 |
Why?
|
| Cloning, Molecular | 2 | 2008 | 897 | 0.140 |
Why?
|
| Genetic Vectors | 3 | 2013 | 936 | 0.130 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2017 | 84 | 0.130 |
Why?
|
| Conserved Sequence | 2 | 2008 | 291 | 0.130 |
Why?
|
| Stem Cells | 2 | 2012 | 707 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2019 | 469 | 0.130 |
Why?
|
| Inflammation | 2 | 2016 | 1447 | 0.130 |
Why?
|
| Protein Domains | 1 | 2017 | 237 | 0.120 |
Why?
|
| Molecular Weight | 1 | 2015 | 387 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2015 | 118 | 0.120 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 981 | 0.110 |
Why?
|
| Ophiopogon | 1 | 2014 | 1 | 0.110 |
Why?
|
| Apoptosis | 4 | 2018 | 1806 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 368 | 0.110 |
Why?
|
| Prostaglandins I | 1 | 2013 | 2 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 576 | 0.110 |
Why?
|
| Gene Expression | 2 | 2008 | 1561 | 0.110 |
Why?
|
| Monocrotaline | 1 | 2013 | 4 | 0.110 |
Why?
|
| Disulfides | 2 | 2004 | 79 | 0.110 |
Why?
|
| Computer Simulation | 2 | 2007 | 651 | 0.110 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 12 | 0.110 |
Why?
|
| Cattle | 2 | 2005 | 569 | 0.100 |
Why?
|
| Hydrazines | 2 | 2003 | 30 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 499 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2003 | 38 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2014 | 140 | 0.100 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2003 | 65 | 0.100 |
Why?
|
| Mutation | 3 | 2017 | 5848 | 0.100 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2014 | 137 | 0.100 |
Why?
|
| Penile Erection | 1 | 2013 | 75 | 0.100 |
Why?
|
| Calcium | 2 | 2011 | 1102 | 0.100 |
Why?
|
| Arginine | 2 | 2006 | 334 | 0.100 |
Why?
|
| Cell Engineering | 1 | 2012 | 21 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 691 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1697 | 0.100 |
Why?
|
| Base Sequence | 4 | 2006 | 3102 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 723 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 48 | 0.090 |
Why?
|
| Erabutoxins | 1 | 1991 | 3 | 0.090 |
Why?
|
| Cobra Neurotoxin Proteins | 1 | 1991 | 6 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 680 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1893 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2013 | 490 | 0.090 |
Why?
|
| Point Mutation | 2 | 2011 | 348 | 0.090 |
Why?
|
| Acetylcholine | 1 | 1991 | 83 | 0.090 |
Why?
|
| Bungarotoxins | 1 | 1990 | 15 | 0.090 |
Why?
|
| Feeder Cells | 1 | 2010 | 9 | 0.090 |
Why?
|
| Growth Inhibitors | 1 | 2010 | 38 | 0.090 |
Why?
|
| Feces | 1 | 2014 | 727 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2010 | 1101 | 0.080 |
Why?
|
| Memory | 1 | 2013 | 361 | 0.080 |
Why?
|
| Biocatalysis | 1 | 2009 | 34 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2013 | 524 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 258 | 0.080 |
Why?
|
| Biomarkers | 2 | 2019 | 3090 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 528 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1694 | 0.080 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2008 | 10 | 0.080 |
Why?
|
| Thromboxane B2 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 186 | 0.080 |
Why?
|
| Radioligand Assay | 1 | 2008 | 26 | 0.080 |
Why?
|
| Phospholipids | 1 | 2009 | 106 | 0.080 |
Why?
|
| Structure-Activity Relationship | 3 | 2006 | 581 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 441 | 0.070 |
Why?
|
| Liposomes | 1 | 2009 | 188 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 489 | 0.070 |
Why?
|
| Titrimetry | 1 | 2007 | 7 | 0.070 |
Why?
|
| Crystallography | 1 | 2007 | 40 | 0.070 |
Why?
|
| Molecular Conformation | 1 | 2007 | 106 | 0.070 |
Why?
|
| Solubility | 1 | 2007 | 139 | 0.070 |
Why?
|
| Protons | 1 | 2007 | 92 | 0.070 |
Why?
|
| DNA Primers | 2 | 2006 | 657 | 0.070 |
Why?
|
| Anxiety | 1 | 2013 | 959 | 0.070 |
Why?
|
| Rats, Inbred F344 | 2 | 2019 | 106 | 0.070 |
Why?
|
| Plant Structures | 1 | 2006 | 3 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 358 | 0.060 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2006 | 12 | 0.060 |
Why?
|
| Templates, Genetic | 1 | 2005 | 97 | 0.060 |
Why?
|
| Anti-Obesity Agents | 1 | 2006 | 41 | 0.060 |
Why?
|
| Sequence Analysis, Protein | 1 | 2005 | 49 | 0.060 |
Why?
|
| Phenylalanine | 1 | 2006 | 128 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 142 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2312 | 0.060 |
Why?
|
| Alanine | 1 | 2006 | 187 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 581 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 376 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2006 | 271 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2018 | 708 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 216 | 0.050 |
Why?
|
| Antibody Specificity | 2 | 2002 | 204 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1498 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 443 | 0.050 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2003 | 22 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 136 | 0.050 |
Why?
|
| Rhodopsin | 1 | 2003 | 64 | 0.050 |
Why?
|
| DNA | 2 | 2003 | 1608 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 462 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 399 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1896 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12392 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 135 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2006 | 556 | 0.050 |
Why?
|
| Fallopian Tubes | 1 | 2002 | 73 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2002 | 190 | 0.050 |
Why?
|
| Rats | 3 | 2013 | 3717 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2002 | 99 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 106 | 0.050 |
Why?
|
| Myasthenia Gravis | 2 | 1992 | 73 | 0.050 |
Why?
|
| Male | 6 | 2020 | 61508 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 270 | 0.050 |
Why?
|
| Oxygen | 1 | 2002 | 555 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 94 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2018 | 78 | 0.040 |
Why?
|
| Calcineurin | 1 | 2018 | 101 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1968 | 0.040 |
Why?
|
| Time Factors | 1 | 2008 | 6333 | 0.040 |
Why?
|
| Female | 6 | 2018 | 66787 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 59 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 662 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1996 | 232 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 778 | 0.030 |
Why?
|
| Epitopes | 2 | 1992 | 433 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 289 | 0.030 |
Why?
|
| Succinic Acid | 1 | 2014 | 14 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 79 | 0.030 |
Why?
|
| Prebiotics | 1 | 2014 | 24 | 0.030 |
Why?
|
| Fermentation | 1 | 2014 | 66 | 0.030 |
Why?
|
| Purines | 1 | 2014 | 116 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 20 | 0.030 |
Why?
|
| Nerve Crush | 1 | 2013 | 8 | 0.030 |
Why?
|
| Autoantibodies | 2 | 1992 | 436 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2014 | 121 | 0.030 |
Why?
|
| 4-Aminopyridine | 1 | 2012 | 32 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 63 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 129 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 81 | 0.020 |
Why?
|
| Half-Life | 1 | 2012 | 158 | 0.020 |
Why?
|
| Fear | 1 | 2013 | 200 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2013 | 326 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 219 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 554 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2013 | 178 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 71 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2012 | 157 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 3348 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 1992 | 154 | 0.020 |
Why?
|
| Torpedo | 1 | 1991 | 37 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 214 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 256 | 0.020 |
Why?
|
| Actins | 1 | 2013 | 346 | 0.020 |
Why?
|
| Hypoxia | 1 | 2012 | 249 | 0.020 |
Why?
|
| Computer Graphics | 1 | 1990 | 38 | 0.020 |
Why?
|
| Metabolomics | 1 | 2014 | 423 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 604 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1241 | 0.020 |
Why?
|
| Intestines | 1 | 2014 | 577 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 806 | 0.020 |
Why?
|
| Microbiota | 1 | 2014 | 389 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 2064 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 4406 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2009 | 344 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 762 | 0.020 |
Why?
|
| Software | 1 | 1990 | 683 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1526 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 240 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2004 | 295 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2006 | 155 | 0.010 |
Why?
|
| Prostaglandins H | 1 | 2002 | 4 | 0.010 |
Why?
|
| Tritium | 1 | 2002 | 173 | 0.010 |
Why?
|
| Adenylyl Cyclases | 1 | 2002 | 83 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 4263 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2002 | 247 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1290 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2006 | 923 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 3071 | 0.010 |
Why?
|
| Valine | 1 | 1996 | 115 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 718 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1992 | 1727 | 0.010 |
Why?
|
| Pyridostigmine Bromide | 1 | 1992 | 13 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 108 | 0.010 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1992 | 5 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1992 | 13 | 0.010 |
Why?
|
| Prednisone | 1 | 1992 | 276 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 261 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1992 | 266 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1992 | 228 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 417 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1992 | 702 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 1585 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1992 | 2821 | 0.000 |
Why?
|
| Aged | 1 | 1992 | 19878 | 0.000 |
Why?
|
| Adolescent | 1 | 1992 | 19356 | 0.000 |
Why?
|
| Middle Aged | 1 | 1992 | 26939 | 0.000 |
Why?
|
| Adult | 1 | 1992 | 29645 | 0.000 |
Why?
|